“Secukinumab in Moderate to Severe Hidradenitis Suppurativa: Primary Endpoint Analysis From the SUNSHINE and SUNRISE Phase 3 Trials”. 2023. SKIN The Journal of Cutaneous Medicine 7 (2): s129. https://doi.org/10.25251/skin.7.supp.129.